echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: TP53 mutation increases radiotherapy resistance of rhabdomyosarcoma and Ewing's sarcoma

    Br J Cancer: TP53 mutation increases radiotherapy resistance of rhabdomyosarcoma and Ewing's sarcoma

    • Last Update: 2021-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    At present, the prognosis of patients with recurrent pediatric sarcoma (RMS) and Ewing's sarcoma (ES) is still very poor, and the long-term survival rate of patients is very low.


    At present, the prognosis of patients with recurrent pediatric sarcoma (RMS) and Ewing's sarcoma (ES) is still very poor, and the long-term survival rate of patients is very low.


    Although there is significant heterogeneity in the response of pediatric sarcoma after radiotherapy, it is currently unclear at the molecular level what drives the radiotherapy sensitivity and resistance of tumor tissues.


    Further, the genomic determinants related to the response to liberation therapy are particularly important.


    Previous studies have shown that p53 plays a key role in the DNA repair process and response to radiotherapy.


    The researchers aimed to determine the TP53 mutation status and the related clinical phenotypes of p53 signaling pathway changes in RMS and ES patients undergoing radiotherapy.



    Related research diagram

    Related research diagram

    The results showed that the median follow-up time for patients was 26 months after radiotherapy.




    Analysis of tumor progression and survival rate of radiotherapy in patients with different TP53 status

    Analysis of tumor progression and survival rate of radiotherapy in patients with different TP53 status

    In summary, the results of this study indicate that TP53 mutations are associated with increased radiotherapy resistance in RMS and ES.


    TP53 mutations are associated with increased resistance to radiation therapy in RMS and ES.



    org/10.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.